Allarity (ALLR) Therapeutics announced plans for the next step in advancing the clinical development of stenoparib toward FDA approval in advanced ovarian cancer. With this new phase 2 protocol, Allarity will capitalize and expand on the ongoing phase 2 clinical trial data to optimize the dose of stenoparib and to refine the DRP patient selection criteria in order to maximize the clinical benefit from stenoparib.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
Questions or Comments about the article? Write to editor@tipranks.com